{"version":"1.0","type":"link","title":"Impact of sex on efficacy and safety of 1st-line treatment with FOLFIRI plus cetuximab or bevacizumab in RAS/BRAF wildtype metastatic colorectal cancer - A subgroup analysis of the FIRE-3 (AIO KRK-0306) trial.","author_name":"Heinrich K 외","author_url":"https://prs-insight.online/author/Heinrich%20K","provider_name":"PRSinsight","provider_url":"https://prs-insight.online","thumbnail_url":"https://prs-insight.online/og/paper/109921","thumbnail_width":1200,"thumbnail_height":630}